fda warning letters compounded semaglutide october 2025 issued 30 to telehealth companies for false and misleading claims about GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading US FDA warns online vendors

I would put a lot of effort into how I dressed, my hair, my makeup, and it would never feel right

The AOAs Evidence-based Optometry Committee offers clinical recommendations for doctors of optometry

Insufficient safety data

The current study involves a representative sub-cohort (including baseline visit and follow-up visits from control schools)

Losing weight isnt always just about counting calories or exercising more

GLP-1 medications can help manage type 2 diabetes and obesity, but they may cause short-term mild-to-moderate side effects such as nausea, vomiting, diarrhoea, constipation, bloating, and decreased appetite, particularly at the beginning of treatment